Forte Biosciences, Inc. - Common Stock — Quarterly Financial Statistics (NASDAQ:FBRX) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Documents

Quarterly Annual

Cash from operating activities -10.36 M-10.06 M-14 M-16.47 M-18.81 M-22.7 M -71.98 M Cash from investing activities 36.29 M0-55 K00-147.84 M -147.9 M Cash from financing activities -2.32 M70.35 M1.32 M9 00074 K161.95 M 163.36 M Free cash flow -10.36 M-10.06 M-14.05 M-16.47 M-18.81 M-22.7 M -72.03 M

News

Alger Small Cap Growth Fund Q2 2026 Portfolio Review

The Charts Reveal Significant Price Movement in Forte Biosciences Stock Ahead of Argenx’s Acquisition Announcement

Stocks Settle Mixed as AI Angst Offsets Easing Geopolitical Tensions

The $2.2 Billion Reason Forte BioSciences (FBRX) Stock Is Skyrocketing Today

Forte: Positive FB102 Vitiligo Treatment Data And Argenx Acquisition For $2.2 Billion

Stocks Fall from Early Highs as Chipmakers Retreat

Big Tech Earnings, Fed's Interest Rate Decision To Keep Next Week Busy

Forte Biosciences, Inc. (FBRX) Discusses Positive Results From FB102 Phase 1b Vitiligo Study and Mechanism of Action - Slideshow (NASDAQ:FBRX) 2026-07-13

Why Is Forte Biosciences (FBRX) Stock Up Today? - TipRanks.com

FBRX Stock Rallies 78% on Positive Early-Stage Vitiligo Study Data

Forte Biosciences: FB102 Is Becoming A Platform Story, Not A Single-Indication Bet (NASDAQ:FBRX)

Forte Biosciences, Inc. (FBRX) Discusses Positive Results From FB102 Phase 1b Vitiligo Study and Mechanism of Action Transcript